Clinical trials: Histological Response
Hepatocellular Carcinoma, Renal Cell Carcinoma
Genome-wide Association Study to Predict Treatment Response for Molecular Targeted Therapy in Hepatocellular Carcinoma and Renal Cell Carcinoma
All Hepatocellular carcinoma and Renal cell carcinoma patients who receive molecular targeted therapy will be candidates for the study.
- Trial name
- NCT01482520
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Samsung Medical Center
Chronic Hepatitis C, Hepatocellular Carcinoma
Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Hepatocellular Carcinoma
Combination therapy with pegylated interferon-alpha plus ribavirin has greatly improved the treatment efficacy and is the mainstream of treatment for chronic hepatitis C infection.
- Trial name
- NCT00834860
- Testing
- peginterferon alpha-2a and ribavirin
- Where
- Taiwan
- Volunteers
- 179 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Oropharynx
Nab-paclitaxel and Carboplatin Followed by Response-Based Local Therapy in Treating Patients With Stage III or IV HPV-Related Oropharyngeal Cancer
This phase II trial studies nab-paclitaxel (paclitaxel albumin-stabilized nanoparticle formulation) and carboplatin followed by response-based local therapy in treating patients with stage III or IV human papillomavirus…
- Conditions
- Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Oropharynx
- Trial name
- OPTIMA (NCT02258659)
- Testing
- paclitaxel albumin-stabilized nanoparticle formulation, carboplatin, radiation therapy
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- University of Chicago
Myeloma
A Study of the Bortezomib, Lenalidomide, and Dexamethasone Regimen for the Treatment of Newly Diagnosed Multiple Myeloma Patients
A real-world prospective registry study for patients with newly diagnosed multiple myeloma (NDMM) has been conducted at the First Affiliated Hospital of Soochow University since August 2018.
- Trial name
- NCT07206810
- Testing
- Bortezomib, Lenalidomide, and Dexamethasone
- Where
- China
- Volunteers
- 419 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Metastatic Head-and-neck Squamous-cell Carcinoma
Circulating Tumor Cells as an Early Predictive head-and -Neck Squamous-cell Carcinoma
In France, the incidence of head and neck squamous cell carcinomas (HNSCC) is 16 000 new cases/year. During these last years, many new chemotherapies and targeted therapies have been developed improving significantly the overall…
- Trial name
- CIRCUTEC (NCT02119559)
- Testing
- Blood analysis by EPISPOT and CellSearch®
- Where
- France
- Volunteers
- 115 people
- Sponsor
- University Hospital, Montpellier
Stage II Grade 1 Follicular Lymphoma, Stage II Grade 2 Follicular Lymphoma
Gazyvaro and Low Dose Radiotherapy in Early Stage Follicular Lymphoma
Combined modality approach using Obitunuzumab and involved site low dose irradiation in early stage nodal follicular lymphoma. Radiation dose will be adapted for low-responders.
- Conditions
- Stage II Grade 1 Follicular Lymphoma, Stage II Grade 2 Follicular Lymphoma, Stage I Follicular Lymphoma Grade 1, Stage II Follicular Lymphoma Grade 2
- Trial name
- GAZAI (NCT03341520)
- Testing
- Obinutuzumab Injection [Gazyva], Low dose radiation Therapy (LDRT)
- Where
- 12 sites in Germany
- Volunteers
- 89 people
- Sponsor
- Heidelberg University
Hepatocellular Carcinoma
Adjuvant IP-001 Treatment for HCC Patients Following Surgical Resection and Ablation or Ablation Alone
The purpose of this study is to evaluate the safety and efficacy of administration of intratumoral IP-001 injection at different dosages (volume and concentration) following local microwave ablation (MWA) or surgical resection…
- Trial name
- NCT06526338
- Testing
- 1.0% IP-001 for injection, Surgical Resection and Local Ablation, Local Ablation Alone
- Where
- United States
- Volunteers
- 315 people
- Sponsor
- Robert C. Martin
Lymphocytic Leukemia, Chronic
A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe)
This randomized, open-label, parallel group study will assess the effect on response rate and the safety of MabThera added to either bendamustine or chlorambucil in patients with chronic lymphocytic leukemia.
- Trial name
- NCT01056510
- Testing
- bendamustine, chlorambucil, rituximab [MabThera/Rituxan]
- Where
- 85 sites in Finland, France and 6 more
- Volunteers
- 357 people
- Sponsor
- Hoffmann-La Roche
Glioblastoma Multiforme
MRI Predictors of Response to Tumor Treating Fields
Patients with glioblastoma, an aggressive brain tumor, are recommended to undergo treatment with tumor treating fields using the Optune device as part of standard of care therapy.
- Trial name
- NCT03642080
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- New York Presbyterian Brooklyn Methodist Hospital
Melanoma, Skin
Omitting Therapeutic Lymph Node Dissection in Patients With Melanoma (Stage 3) and Major Pathological Response in the Index Lymph Node
Rationale: The randomized trial NADINA has demonstrated that neoadjuvant treatment with nivolumab with ipilimumab improves event-free survival (EFS) in patients with macroscopic resectable stage III melanoma.
- Trial name
- OMIT (NCT06754904)
- Testing
- Omitting TLND, Index node procedure
- Where
- Netherlands
- Volunteers
- 213 people
- Sponsor
- D.J. (Dirk) Grünhagen
Extraocular Extension Melanoma, Metastatic Intraocular Melanoma
Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery
This phase II trial studies how well axitinib works in treating patients with melanoma that has spread to other places in the body or cannot be removed by surgery.
- Conditions
- Extraocular Extension Melanoma, Metastatic Intraocular Melanoma, Recurrent Intraocular Melanoma, Recurrent Melanoma
- Trial name
- NCT01533948
- Testing
- axitinib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Roswell Park Cancer Institute
Glioblastoma, Glioblastoma Multiforme
Anti-Cancer Effects of Carvedilol With Standard Treatment in Glioblastoma and Response of Peripheral Glioma Circulating Tumor Cells
The purpose of this pilot study is to evaluate the addition of carvedilol with standard of care treatment to determine if it will improve progression-free survival in the front line setting in patients with glioblastoma…
- Trial name
- NCT03980249
- Testing
- Carvedilol
- Where
- United States
- Sponsor
- West Virginia University
Hodgkin Lymphoma
FIL Study on ABVD DD-DI as Upfront Therapy in HL.
The FIL-Rouge is a randomized, open-label, multicenter, phase III, 2-arm study. The primary objective is to compare efficacy and tolerability of the intensified variant 'dose-dense/dose-intense ABVD' (ABVD DD-DI) with an interim…
- Trial name
- NCT03159897
- Testing
- Doxorubicin, Bleomycin, Vinblastine
- Where
- 46 sites in Italy
- Volunteers
- 500 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Sarcoma
Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype
This is a randomized open label study, with 2 arms treatments conducted in patients with metastatic or unresectable advanced sarcoma of rare subtype; previously treated by anthracycline-based regimen except for whom standard…
- Trial name
- RAR-Immune (NCT04741438)
- Testing
- Nivolumab and IPILIMUMAB, Pazopanib Oral Tablet [Votrient]
- Where
- 13 sites in France
- Volunteers
- 96 people
- Sponsor
- Centre Leon Berard
Oesophageal Adenocarcinoma, Tumor Microenvironment
Metformin as a Metabolic Intervention in Oesophageal Adenocarcinomas to Improve Response to Neoadjuvant Chemoradiotherapy
The primary objective of this study is to investigate whether two weeks of metformin treatment can activate the tumour microenvironment in patients with stage II and III oesophageal adenocarcinomas.
- Trial name
- MEMENTO (NCT06687876)
- Testing
- Metformin
- Where
- 2 sites in Netherlands
- Volunteers
- 14 people
- Sponsor
- Amsterdam UMC, location VUmc
Lymphoma
Vaccine Therapy Following Chemotherapy & Peripheral Stem Cell Transplantation in Treating Non-Hodgkin's Lymphoma
RATIONALE: Vaccines made from a person's cancer cells may make the body build an immune response to kill cancer cells. Vaccine therapy may be an effective treatment for non-Hodgkin's lymphoma.
- Trial name
- NCT00006478
- Testing
- autologous tumor cell vaccine, keyhole limpet hemocyanin, sargramostim
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Nebraska
Vestibular Schwannoma
MR Fingerprinting for Vestibular Schwannomas
MR Fingerprinting (MRF) will be performed in patients who will be treated with Gamma Knife radio surgery for a vestibular schwannoma before the intervention.
- Trial name
- NCT04851925
- Testing
- MR Fingerprinting
- Where
- Austria
- Volunteers
- 50 people
- Sponsor
- Medical University of Vienna
Lymphoma, Large B-Cell, Diffuse
Non-invasive Tumor Immunoglobulin Gene Next Generation Sequencing (IgNGS) in Diffuse Large B Cell Lymphoma (DLBCL)
This study will evaluate IgNGS at different time points in newly diagnosed DLBCL patients homogeneously treated (RCHOP) to address its correlation with conventional techniques (i.e., positron emission tomography/computed…
- Trial name
- NCT04237168
- Testing
- IgNGS from circulating tumor DNA
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Lymphocytic Leukemia, Chronic
A Study of MabThera (Rituximab) Plus Chlorambucil in Participants With Chronic Lymphocytic Leukemia.
This single arm study will assess the safety and effect on response rate of a combination of rituximab and chlorambucil in previously untreated participants with B-cell chronic lymphocytic leukemia.
- Trial name
- NCT00532129
- Testing
- Rituximab, Chlorambucil
- Where
- 12 sites in United Kingdom
- Volunteers
- 100 people
- Sponsor
- Hoffmann-La Roche
Chronic Myeloid Leukemia, Chronic Phase, Adult CML
Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase
This study is a multicenter Phase 2, non-randomized, open-label single-group frontline study administering asciminib in patients with newly diagnosed Chronic Myeloid Leukemia-Chronic Phase (CML-CP).
- Conditions
- Chronic Myeloid Leukemia, Chronic Phase, Adult CML, Leukemia, Myeloid, Leukemia,Myeloid, Chronic
- Trial name
- ALERTCML (NCT05143840)
- Testing
- Single Agent Asciminib, Low TKI, Elective Free Treatment
- Where
- 8 sites in United States
- Volunteers
- 100 people
- Sponsor
- University of Alabama at Birmingham
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.